AIM AIM ImmunoTech Inc

Price (delayed)

$2.01

Market cap

$96.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.36

Enterprise value

$49.59M

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease ...

Highlights
AIM ImmunoTech's equity has surged by 102% YoY and by 16% QoQ
The debt has dropped by 66% year-on-year and by 2.9% since the previous quarter
The net income has decreased by 44% YoY
AIM ImmunoTech's gross margin has decreased by 29% YoY and by 20% from the previous quarter

Key stats

What are the main financial stats of AIM
Market
Shares outstanding
47.83M
Market cap
$96.14M
Enterprise value
$49.59M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.35
Price to sales (P/S)
629.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
339.65
Earnings
Revenue
$146,000
EBIT
-$13.78M
EBITDA
-$13.21M
Free cash flow
-$10.37M
Per share
EPS
-$0.36
Free cash flow per share
-$0.23
Book value per share
$1.48
Revenue per share
$0
TBVPS
$1.58
Balance sheet
Total assets
$74.09M
Total liabilities
$3.12M
Debt
$2.22M
Equity
$70.97M
Working capital
$50.25M
Liquidity
Debt to equity
0.03
Current ratio
52.8
Quick ratio
51.52
Net debt/EBITDA
3.53
Margins
EBITDA margin
-9,044.5%
Gross margin
-474.7%
Net margin
-9,718.5%
Operating margin
-10,678.1%
Efficiency
Return on assets
-22.4%
Return on equity
-23.6%
Return on invested capital
-59.5%
Return on capital employed
-18.9%
Return on sales
-9,441.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AIM stock price

How has the AIM ImmunoTech stock price performed over time
Intraday
-1.47%
1 week
1.52%
1 month
-7.8%
1 year
-34.53%
YTD
12.29%
QTD
-6.51%

Financial performance

How have AIM ImmunoTech's revenue and profit performed over time
Revenue
$146,000
Gross profit
-$693,000
Operating income
-$15.59M
Net income
-$14.19M
Gross margin
-474.7%
Net margin
-9,718.5%
The net margin has dropped by 82% year-on-year and by 10% since the previous quarter
The company's operating margin has shrunk by 54% YoY and by 15% QoQ
The net income has decreased by 44% YoY
AIM ImmunoTech's gross margin has decreased by 29% YoY and by 20% from the previous quarter

Growth

What is AIM ImmunoTech's growth rate over time

Valuation

What is AIM ImmunoTech stock price valuation
P/E
N/A
P/B
1.35
P/S
629.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
339.65
The company's EPS rose by 39% YoY and by 20% QoQ
AIM ImmunoTech's equity has surged by 102% YoY and by 16% QoQ
The P/B is 3.8% higher than the 5-year quarterly average of 1.3 but 3.6% lower than the last 4 quarters average of 1.4
AIM's P/S is 31% above its last 4 quarters average of 482.3
AIM ImmunoTech's revenue has decreased by 21% YoY and by 10% QoQ

Efficiency

How efficient is AIM ImmunoTech business performance
The company's return on sales has shrunk by 87% YoY and by 12% QoQ
The ROE has soared by 59% YoY and by 16% from the previous quarter
AIM's ROA is up by 43% YoY and by 14% QoQ
The return on invested capital has declined by 15% year-on-year but it has increased by 5% since the previous quarter

Dividends

What is AIM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AIM.

Financial health

How did AIM ImmunoTech financials performed over time
The total assets has surged by 75% year-on-year and by 15% since the previous quarter
The company's total liabilities has shrunk by 57% YoY and by 5% QoQ
The debt is 97% smaller than the equity
AIM ImmunoTech's equity has surged by 102% YoY and by 16% QoQ
AIM's debt to equity has dropped by 84% year-on-year and by 25% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.